CoChat

Efficacy of duloxetine add on in treatment of inflammatory bowel disease patients: A double-blind controlled study

Open access
Sharbafchi, MohammadReza, Daghaghzadeh, Hamed, Naji, Fateme, Afshar, Hamid, Feizi, Awat, Maroufi, Mohsen, Tabatabaeeyan, Mahshid, Adibi, Peyman, Tavakoli, Hamid · 2015 · Journal of Research in Medical Sciences
Cited by 56

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Treating inflammatory bowel disease (IBD) with antidepressants might be of utility to improve patient's condition. The aim of this study was to assess the efficacy of Duloxetine on depression, anxiety, severity of symptoms, and quality of life (QOL) in IBD patients. MATERIALS AND METHODS: In a randomized, double-blind, controlled clinical trial on 2013-2014, in Alzahra Hospital (Isfahan, Iran), 44 IBD patients were chosen to receive either duloxetine (60 mg/day) or placebo. They were treated in a 12 weeks program, and all of the participants also received mesalazine, 2-4 g daily. We assessed anxiety and depression with Hospital Anxiety and Depression Scale, the severity of symptoms with Lichtiger Colitis Activity Index and QOL with World Health Organization Quality of Life Instruments, before and just after the treatment. The data were analyzed using Paired sample t-test and ANCOVA. RESULTS: In 35 subjects who completed the study, the mean (standard error [SE]) scores of depression and anxiety were reduced in duloxetine more than placebo group, significantly (P = 0.041 and P = 0.049, respectively). The mean (SE) scores of severity of symptom were also reduced in duloxetine more than the placebo group, significantly (P = 0.02). The mean (SE) scores of physical, psychological, and social dimensions of QOL were increased after treatment with duloxetine more than placebo group, significantly (P = 0.001, P = 0.038, and P = 0.015, respectively). The environmental QOL was not increased significantly (P = 0.260). CONCLUSION: Duloxetine is probably effective and safe for reducing depression, anxiety and severity of physical symptoms. It also could increase physical, psychological, and social QOL in patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.4103/1735-1995.165969

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Research works printed but not linked: 25

  1. Bernstein, 2010, A prospective population-based study of triggers of symptomatic flares in IBD, Am J Gastroenterol, 1994
  2. Schoultz, 2013, Assessment of causal link between psychological factors and symptom exacerbation in inflammatory bowel disease: A protocol for systematic review of prospective cohort studies, Syst Rev, 8
  3. Filipovic, 2007, Depression and anxiety levels in therapy-naive patients with inflammatory bowel disease and cancer of the colon, World J Gastroenterol, 438
  4. Rosenkranz, 2007, Substance P at the nexus of mind and body in chronic inflammation and affective disorders, Psychol Bull, 1007
  5. Rook, 2008, The hygiene hypothesis and psychiatric disorders, Trends Immunol, 150
  6. Graff, 2010, It′s not just about the gut: Managing depression and anxiety in inflammatory bowel disease, Pract Gastroenterol, 11
  7. Clarke, 2009, Can antidepressants influence the course of inflammatory bowel disease.The current state of research?, Eur Gastroenterol Hepatol Rev, 48
  8. Mikocka-Walus, 2012, A magic pill.A qualitative analysis of patients′ views on the role of antidepressant therapy in inflammatory bowel disease (IBD)?, BMC Gastroenterol, 93
  9. Janke, 2005, Determinants of life satisfaction in inflammatory bowel disease, Inflamm Bowel Dis, 272
  10. Yates, 2004, Clinical features of depressed outpatients with and without co-occurring general medical conditions in STARFNx01D, Gen Hosp Psychiatry, 421
  11. Mikocka-Walus, 2007, "It doesn′t do any harm, but patients feel better": A qualitative exploratory study on gastroenterologists′ perspectives on the role of antidepressants in inflammatory bowel disease, BMC Gastroenterol, 38
  12. Hansen, 2005, Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder, Ann Intern Med, 415
  13. Kubera, 2000, The effect of repeated amitriptyline and desipramine administration on cytokine release in C57BL/6 mice, Psychoneuroendocrinology, 785
  14. Menon, 2011, A global perspective on gastrointestinal diseases, Gastroenterol Clin North Am, 427
  15. Bjelland, 2002, The validity of the Hospital Anxiety and Depression Scale.An updated literature review, J Psychosom Res, 69
  16. Lichtiger, 1994, Cyclosporine in severe ulcerative colitis refractory to steroid therapy, N Engl J Med, 1841
  17. Development, 1998, The WHOQOL Group, Psychol Med, 551
  18. Diamond, 2006, Antidepressants suppress production of the Th1 cytokine interferon-gamma, independent of monoamine transporter blockade, Eur Neuropsychopharmacol, 481
  19. Iyengar, 2004, Efficacy of duloxetine, a potent and balanced serotonin-norepinephrine reuptake inhibitor in persistent pain models in rats, J Pharmacol Exp Ther, 576
  20. Lipkovich, 2014, Typology of patients with fibromyalgia: Cluster analysis of duloxetine study patients, BMC Musculoskelet Disord, 450
  21. Spiller, 2009, Overlap between irritable bowel syndrome and inflammatory bowel disease, Dig Dis, 48
  22. Bryant, 2011, Functional gastrointestinal disorders in inflammatory bowel disease: Impact on quality of life and psychological status, J Gastroenterol Hepatol, 916
  23. Brennan, 2009, Duloxetine in the treatment of irritable bowel syndrome: An open-label pilot study, Hum Psychopharmacol, 423
  24. Mikocka-Walus, 2006, Antidepressants and inflammatory bowel disease: A systematic review, Clin Pract Epidemiol Ment Health, 24
  25. Rochelle, 2013, The importance of illness perceptions, quality of life and psychological status in patients with ulcerative colitis and Crohn′s disease, J Health Psychol, 972

Cited by

See all 56

Metadata

Authors
Sharbafchi, M., Daghaghzadeh, H., Naji, F., Afshar, H., Feizi, A., Maroufi, M., Tabatabaeeyan, M., Adibi, P., & Tavakoli, H.
Venue
Journal of Research in Medical Sciences
Publisher
Medknow
Published
2015
Volume
20
Issue
6
Pages
595
ISSN
1735-1995 (ISSN-L)
OpenAlex
W2269262916
Cited by
56
References
15
FWCI
2.26
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy of duloxetine add on in treatment of inflammatory bowel disease patients: A double-blind controlled study. https://app.cochat.ai/papers/10.4103/1735-1995.165969
The paper
Sharbafchi, M., Daghaghzadeh, H., Naji, F., Afshar, H., Feizi, A., Maroufi, M., Tabatabaeeyan, M., Adibi, P., & Tavakoli, H. (2015). Efficacy of duloxetine add on in treatment of inflammatory bowel disease patients: A double-blind controlled study. Journal of Research in Medical Sciences. https://doi.org/10.4103/1735-1995.165969

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.